Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Thoracic 1NET 1Dermatologic 1CNS 1

Conditions

Pleural Effusion 1Lymphangiomyoma 1Lymphangioleiomyomatosis 1Chylous Ascites 1Chylothorax 1Ascites 1

Interventions

Cisplatin 71Carboplatin 68Paclitaxel 57Radiotherapy 43Specimen Handling 37Gemcitabine 36Erlotinib Hydrochloride 32Etoposide 30Magnetic Resonance Spectroscopy 29Docetaxel 28Taxes 27Pemetrexed 23Platinum 20Vinorelbine 191,2-diaminocyclohexaneplatinum II citrate 19Bevacizumab 18Cyclophosphamide 16Biopsy 16Radiation 15pembrolizumab 14Immunoglobulin G 12Disulfides 12Topotecan 11Gefitinib 11durvalumab 9atezolizumab 9aldesleukin 9Nivolumab 9Irinotecan 9Bortezomib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Octreotide × Thoracic × Clear all
NCT00005906 2010-04-30

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
4 enrolled 8 charts
Thoracic

Ascites, Chylous Ascites, Chylothorax, Lymphangiomyoma, Pleural Effusion, Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡